Astrazeneca plc, Pharmaceutical company

New Delhi, June 23 AstraZeneca said new data from Public Health England (PHE) demonstrated COVID-19 Vaccine AstraZeneca, offers high levels of protection against the Delta variant (B.1.617.2; formerly the ‘Indian variant).AstraZeneca vaccine is used in India as Covishield. Real world data from PHE, demonstrated two doses of COVID-19 Vaccine AstraZeneca are 92% effective against hospitalisation due to the Delta variant and showed no deaths among those vaccinated.The vaccine also showed a high level of effectiveness against the Alpha variant (B.1.1.7; formerly the ‘Kent' variant) with an 86% reduction of hospitalisations and no deaths reported.The higher efficacy against severe disease and hospitalisation is supported by recent data showing strong T-cell response to COVID-19 Vaccine AstraZeneca, which should correlate with high and durable protection.1Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: "This real world evidence shows that COVID-19 Vaccine AstraZeneca provides a high level of protection against the Delta variant, which is currently a critical area of concern given its rapid transmission. The data show that the vaccine will continue to have a significant impact around the world given that it continues to account for the overwhelming majority of supplies to India and the COVAX facility."The analysis included 14,019 cases of the Delta variant – 122 of whom were hospitalised – between 12 April and 4 June, looking at emergency hospital admissions in England.This real world evidence against the Delta variant is based on limited follow up after the second dose which could impact the effectiveness estimate.The Delta variant is a key contributor to the current wave of infection in the Indian subcontinent and beyond. It has recently replaced the Alpha variant as the dominant strain in Scotland and is responsible for a notable increase in cases in the UK. The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has recommended COVID-19 Vaccine AstraZeneca in countries where new variants, like the Delta variant of concern, are prevalent.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Astrazeneca PlcFOLLOW

Astrazeneca plc, Latest News

London, June 29 Taking the first dose of Pfizer Covid vaccine and then AstraZeneca for the second can ... ...

Amid the global shortage of the COVID-19 vaccines, a study conducted by Oxford University has found out that alternating doses of the AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against the coronavirus. ...

London, June 28 British-Swedish biopharmaceutical firm AstraZeneca has in partnership with the University of Oxford rolled out human ... ...

Colombo, June 26 Sri Lanka hopes to vaccinate all citizens above the age of 30 years against Covid-19 ... ...

Japan will donate one million COVID-19 vaccine doses each to Indonesia, Malaysia, the Philippines, and Thailand starting from next Thursday, said Foreign Minister Toshimitsu Motegi on Friday. ...

Mortality rate from COVID-19 among people older than 60 declined by 70-80 per cent after vaccination with Russia's Sputnik V or AstraZeneca jabs, the Argentinian health ministry said on Friday. ...

Mortality rate from COVID-19 among people older than 60 declined by 70-80 per cent after vaccination with Russia's Sputnik V or AstraZeneca jabs, the Argentinian health ministry said on Friday. ...

New Delhi, June 23 AstraZeneca said new data from Public Health England (PHE) demonstrated COVID-19 Vaccine AstraZeneca, offers ... ...